clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
Published 1 year ago • 120 plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
2:25
outcomes & healthcare utilization cost of patients with cll refractory to btk and bcl-2 inhibitors
-
3:36
outcomes of patients with newly diagnosed crlf2-rearranged b-all
-
2:49
insights into the role of novel btkis in the treatment landscape of r/r cll
-
2:34
sequencing of therapies in patients with r/r cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
6:24
indiko biochemistry analyzer demonstration
-
9:25
mgus diagnosis: a step-by-step approach
-
9:53
flow cytometry - 4 | cd markers| t cell acute lymphoblastic leukemia & nk cells -- 10 minutes !!!!
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
3:03
outcomes following venetoclax monotherapy in patients with r/r wm in the real-world setting
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:17
an ongoing phase i/ii study of sonrotoclax zanubrutinib in patients with treatment-naive cll/sll
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
2:41
btk and plcg2 mutations in cll patients taking ibrutinib
-
2:05
alnuctamab: improved route of administration and optimized dose level & dosing schedule
-
0:45
difference between quality of life & patient-reported outcomes
-
2:15
cd8 t cell expansion in cll patients treated with ibrutinib
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial